The ingredient is delivered in the company’s Matrix technology that protects particles of MK-7 without coating, additives, or additional ingredients.
Gnosis by Lesaffre (Marcq-en-Baroeul, France) will debut a new iteration of its MenaQ7 vitamin K2 MK-7 ingredient at the SupplySide West trade show, taking place October 31 to November 4, 2022, in Las Vegas (Booth #4652). The new ingredient, called MenaQ7 Matrix, features the company’s award-winning Matrix technology that protects particles of MK-7 without the use of coating, additives, or additional ingredients.
“Ensuring the stability of menaquinone ingredients can be as complex as the finished-product formulations that brand owners are conceiving,” the company explains in a press release. “Research shows that moisture and mineral salts are critical variables for degradation, driving the need for a protective technology to shelter the menaquinone molecules during shelf life. Launched in December 2021, Matrix is the result of a proprietary technology that protects the particles of MK-7 with no coating, additives, or additional ingredients, providing a less cumbersome and more predictable formulation process for complex K2 products.”
Manufacturers can see numerous benefits from Matrix, including stability and homogeneity, which reduces the need for overages, as well as a cleaner label since the technology doesn’t involve the use of additives, the company says.
In the press release, Xavier Berger, global market manager forGnosis by Lesaffre, added, “Stability is a constant issue facing commercial partners who desire to create complex vitamin K2 formulations. That process is now more efficient because the Matrix technology embeds the K2 as MK-7 particles in the product, thus leading to faster market introductions. Matrix was explicitly developed for vitamin K2; it is not an adaptation of an existing technology previously utilized for other ingredients.”